

**Supplement Table 1. Literature documenting less frequently utilized agents demonstrating variable response or no response, by drug, for patients with relapsed or refractory HB or HCC.**

Treatment	Number of patients	Reported Response	Reference	Quality Rating
<b>Variable or no response</b>				
<b>DOCETAXEL</b>				
Docetaxel	2 HB	2 NR	<sup>1</sup> Blaney 1997	2
Docetaxel	1 HB	1 NR	<sup>2</sup> Seibel 1999	2
Docetaxel	5 HB	Cohorted data: 5 SD or PD	<sup>3</sup> Zwerdling 2006	2
Docetaxel	5 HB	1 CR (+ pulm RT); 1 decrease AFP with SD then PD; 2 PD; 1 inevaluable	<sup>4</sup> George 2012	2
<b>PACLITAXEL</b>				
Paclitaxel	1 HB	1 NR	<sup>5</sup> Doz 2001	2
Paclitaxel	1 HB	1 NR	<sup>6</sup> Hayashi 2003	2
<b>OTHER</b>				
6-mercaptopurine	2 HB, 1 HCC	2 PD (HB and HCC); 1 SD (HCC)	<sup>7</sup> Adamson 1990	2
Interleukin-2	1 HB, 1 HCC	1 PR (HB); 1 NR (HCC)	<sup>8</sup> Chien 1990	2
Methotrexate	4	2 PR by AFP decline but died of toxicity; 1 SD, 1 PD	<sup>9</sup> Weitman 1991	4
Interleukin-2	2 HB	2 NR	<sup>10</sup> Pais 1992	2
All-trans-retinoic acid and interferon $\alpha$ 2a	1 HB	1 NR	<sup>11</sup> Adamson 1997	2
Topotecan	8 HB	2 SD; 6 NR	<sup>12</sup> Nitschke 1998	2

Topotecan/carbo	3 HB	3 SD	<sup>13</sup> Athale 2002	2
Topotecan/cisplatin	2 HB	2 Decrease in AFP	<sup>14</sup> Wells 2002	2
Bortezomib	1 HB	1NR	<sup>15</sup> Blaney 2004	2
High-dose CTX	17 HB	1 CR; 1 SD; 15 PD	<sup>16</sup> Cacciavillano 2004	2
Gefitinib	1 HB	1 NR (or not evaluable)	<sup>17</sup> Daw 2005	2
Ecteinascidin-743	1 HB	1 NR (or not evaluable)	<sup>18</sup> Lau 2005	2
Flavopiridol	1 HB	1 NR (or not evaluable)	<sup>19</sup> Whitlock 2005	2
Depsipeptide	1 HB	1 NR	<sup>20</sup> Fouladi 2006	2
Celecoxib & vinblastine	1 HB	1 NR	<sup>21</sup> Stempak 2006	2
Fenretinide	2 HB	2 PD	<sup>22</sup> Villablanca 2006	2
Pemetrexed	2 HB	2 NR	<sup>23</sup> Malempati 2007	2
BCL2 antisense oligonucleotide, doxo/CTX	3 HB	3 NR	<sup>24</sup> Rheingold 2007	2
17-AAG	1 HB	1 SD	<sup>25</sup> Weigel 2007	2
Bevacizumab	2 HB	2 NR	<sup>26</sup> Glade Bender 2008	2
Rebeccamycin analogue	2 HB, 4 HCC	6 NR	<sup>27</sup> Langevin 2008	2
Oxaliplatin	10 HB	10 PD	<sup>28</sup> Beaty 2010	2
Ispinesib	3 HB	3 NR	<sup>29</sup> Souid 2010	2
Dasatanib	3 HB	3 NR	<sup>30</sup> Aplenc 2011	2
Lenalidomide	2 HB	2 NR	<sup>31</sup> Berg 2011	2
Aflibercept	6 HB, 1 HCC	1 SD (HB); 1 SD (HCC); 5 NR	<sup>32</sup> Glade Bender 2012	2


Sorafenib/bevacizumab	1 HB	Decreased size and AFP	<sup>33</sup> Marsh 2012	5
Lexatumumab	3 HB	1 Decrease in AFP then PD	<sup>34</sup> Merchant 2012	2
Alisertib	8 HB	1 PR	<sup>35,36</sup> Mosse 2012, 2019	2
Sorafenib	4 HB	4 NR	<sup>37</sup> Widemann 2012	2
Pazopanib	2 HB	1 PR	<sup>38</sup> Glade Bender 2013	2
Vorinostat & bortezomib	1 HB	1 NR	<sup>39</sup> Muscal 2013	2
Cixutumumab	10 HB	10 NR	<sup>40</sup> Weigel 2014	2
Reolysin	2 HB	2 NR	<sup>41</sup> Kolb 2015	2
Ruxolitinib	1 HB	1 NR	<sup>42</sup> Loh 2015	2
Tivantinib	1 HB, 1 FLC	2 NR	<sup>43</sup> Geller 2017	2
Cabozantinib	2 HB	2 NR	<sup>44</sup> Chuk 2018	2
Axitinib	1 HB, 1 FLC	1 NR; 1 SD (FLC)	<sup>45</sup> Geller 2018	2
Ontuxizumab	1 HB	1 PD	<sup>46</sup> Norris 2018	2
Eribulin	2 HB	2 NR	<sup>47</sup> Schafer 2018	2
Volasertib	1 HB	1 NR	<sup>48</sup> Doz 2019	2
Rapamycin & irinotecan	3 HB	2 SD, 1 PD	<sup>49</sup> Jannier 2020	2
Talazoparib/tem	1	Data cohorted: 1 SD or NR	<sup>50</sup> Schafer 2020	2
Topotecan/oxaliplatin/VCR	12 HB	Incomplete report: 3 PR, 2 PD, 3 SD	<sup>51</sup> Zhang 2020	4

AFP, alpha-fetoprotein; CR, complete response; CTX, cyclophosphamide; FLC, fibrolamellar carcinoma; HB, hepatoblastoma; NR, no response; PD, progressive disease; PR, partial response; SD, stable disease;

**Supplement Table 2: Anticipated participation by continent and country worldwide.**

<b>Continent</b>	<b>Country</b>	<b>Anticipated Participation</b>
Australia	Australia	11 institutions
	New Zealand	
Asia	Japan	52 institutions
	Hong Kong	1 institution
Europe	Belgium	6 institutions
	France	National database
	Germany	National database
	Ireland	1 institution
	Italy	6 institutions
	Netherlands	National database
	Poland	National database
	Spain	8 institutions
	Switzerland	9 institutions
	United Kingdom	10 institutions
North America	Canada	1 institution
	USA	6 institutions

**Supplement Figure 1: Working timeline demonstrating progress surrounding the inception, design, and activation of the RELIVE relapsed consortium and protocol.**



## Supplemental References

- 1 Blaney, S. M. *et al.* Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. *J Clin Oncol* **15**, 1538-1543 (1997).  
<https://doi.org:10.1200/JCO.1997.15.4.1538>
- 2 Seibel, N. L. *et al.* Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. *Clin Cancer Res* **5**, 733-737 (1999).
- 3 Zwerdling, T. *et al.* Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group. *Cancer* **106**, 1821-1828 (2006).  
<https://doi.org:10.1002/cncr.21779>
- 4 George, S. L., Broster, S., Chisholm, J. C. & Brock, P. Docetaxel in the treatment of children with refractory or relapsed hepatoblastoma. *J Pediatr Hematol Oncol* **34**, e295-297 (2012).  
<https://doi.org:10.1097/MPH.0b013e3182441588>
- 5 Doz, F. *et al.* Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. *Br J Cancer* **84**, 604-610 (2001).  
<https://doi.org:10.1054/bjoc.2000.1637>
- 6 Hayashi, R. J. *et al.* Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study. *J Pediatr Hematol Oncol* **25**, 539-542 (2003). <https://doi.org:10.1097/00043426-200307000-00008>
- 7 Adamson, P. C. *et al.* A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. *Cancer Chemother Pharmacol* **26**, 343-344 (1990). <https://doi.org:10.1007/BF02897290>
- 8 Chien, C. H. & Hsieh, K. H. Interleukin-2 immunotherapy in children. *Pediatrics* **86**, 937-943 (1990).
- 9 Weitman, S. D., Kato, G. J., Barbosa, J. L. & Kamen, B. A. Low-dose methotrexate therapy for hepatoblastoma. *Cancer Chemother Pharmacol* **28**, 233-234 (1991).  
<https://doi.org:10.1007/BF00685519>
- 10 Pais, R. C. *et al.* Phase I study of recombinant human interleukin-2 for pediatric malignancies: feasibility of outpatient therapy. A Pediatric Oncology Group Study. *J Immunother (1991)* **12**, 138-146 (1992). <https://doi.org:10.1097/00002371-199208000-00009>
- 11 Adamson, P. C. *et al.* Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. *J Clin Oncol* **15**, 3330-3337 (1997).  
<https://doi.org:10.1200/JCO.1997.15.11.3330>
- 12 Nitschke, R. *et al.* Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. *J Pediatr Hematol Oncol* **20**, 315-318 (1998).  
<https://doi.org:10.1097/00043426-199807000-00006>
- 13 Athale, U. H. *et al.* Phase I study of combination topotecan and carboplatin in pediatric solid tumors. *J Clin Oncol* **20**, 88-95 (2002). <https://doi.org:10.1200/JCO.2002.20.1.88>
- 14 Wells, R. J. *et al.* Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. *J Pediatr Hematol Oncol* **24**, 89-93 (2002).  
<https://doi.org:10.1097/00043426-200202000-00006>
- 15 Blaney, S. M. *et al.* Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). *J Clin Oncol* **22**, 4804-4809 (2004). <https://doi.org:10.1200/JCO.2004.12.185>

- 16 Cacciavillano, W. D. *et al.* Phase II study of high-dose cyclophosphamide in relapsing and/or resistant hepatoblastoma in children: a study from the SIOPEL group. *Eur J Cancer* **40**, 2274-2279 (2004). <https://doi.org:10.1016/j.ejca.2004.01.042>
- 17 Daw, N. C. *et al.* Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. *J Clin Oncol* **23**, 6172-6180 (2005). <https://doi.org:10.1200/JCO.2005.11.429>
- 18 Lau, L. *et al.* A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. *Clin Cancer Res* **11**, 672-677 (2005).
- 19 Whitlock, J. A. *et al.* Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study. *J Clin Oncol* **23**, 9179-9186 (2005). <https://doi.org:10.1200/JCO.2004.01.0660>
- 20 Children's Oncology, G. *et al.* Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. *J Clin Oncol* **24**, 3678-3685 (2006). <https://doi.org:10.1200/JCO.2006.06.4964>
- 21 Stempak, D. *et al.* A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. *J Pediatr Hematol Oncol* **28**, 720-728 (2006). <https://doi.org:10.1097/01.mph.0000243657.64056.c3>
- 22 Children's Oncology, G. *et al.* Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). *J Clin Oncol* **24**, 3423-3430 (2006). <https://doi.org:10.1200/JCO.2005.03.9271>
- 23 Malempati, S. *et al.* Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. *J Clin Oncol* **25**, 1505-1511 (2007). <https://doi.org:10.1200/JCO.2006.09.1694>
- 24 Rheingold, S. R. *et al.* Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. *J Clin Oncol* **25**, 1512-1518 (2007). <https://doi.org:10.1200/JCO.2006.09.5125>
- 25 Weigel, B. J. *et al.* A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. *Clin Cancer Res* **13**, 1789-1793 (2007). <https://doi.org:10.1158/1078-0432.CCR-06-2270>
- 26 Glade Bender, J. L. *et al.* Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. *J Clin Oncol* **26**, 399-405 (2008). <https://doi.org:10.1200/JCO.2007.11.9230>
- 27 Langevin, A. M. *et al.* A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. *Pediatr Blood Cancer* **50**, 577-580 (2008). <https://doi.org:10.1002/pbc.21274>
- 28 Beaty, O., 3rd *et al.* A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. *Pediatr Blood Cancer* **55**, 440-445 (2010). <https://doi.org:10.1002/pbc.22544>
- 29 Souid, A. K. *et al.* A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study. *Pediatr Blood Cancer* **55**, 1323-1328 (2010). <https://doi.org:10.1002/pbc.22609>
- 30 Aplenc, R. *et al.* Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. *J Clin Oncol* **29**, 839-844 (2011). <https://doi.org:10.1200/JCO.2010.30.7231>
- 31 Berg, S. L. *et al.* Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a

- Children's Oncology Group Phase I Consortium report. *J Clin Oncol* **29**, 316-323 (2011).  
<https://doi.org:10.1200/JCO.2010.30.8387>
- 32 Glade Bender, J. *et al.* A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report. *Clin Cancer Res* **18**, 5081-5089 (2012). <https://doi.org:10.1158/1078-0432.CCR-12-0078>
- 33 Marsh, A. M., Lo, L., Cohen, R. A. & Feusner, J. H. Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP. *Pediatr Blood Cancer* **59**, 939-940 (2012). <https://doi.org:10.1002/pbc.24171>
- 34 Merchant, M. S. *et al.* Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. *J Clin Oncol* **30**, 4141-4147 (2012).  
<https://doi.org:10.1200/JCO.2012.44.1055>
- 35 Mosse, Y. P. *et al.* Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. *Clin Cancer Res* **18**, 6058-6064 (2012).  
<https://doi.org:10.1158/1078-0432.CCR-11-3251>
- 36 Mosse, Y. P. *et al.* A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). *Clin Cancer Res* **25**, 3229-3238 (2019). <https://doi.org:10.1158/1078-0432.CCR-18-2675>
- 37 Widemann, B. C. *et al.* A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. *Clin Cancer Res* **18**, 6011-6022 (2012). <https://doi.org:10.1158/1078-0432.CCR-11-3284>
- 38 Glade Bender, J. L. *et al.* Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. *J Clin Oncol* **31**, 3034-3043 (2013).  
<https://doi.org:10.1200/JCO.2012.47.0914>
- 39 Muscal, J. A. *et al.* A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). *Pediatr Blood Cancer* **60**, 390-395 (2013). <https://doi.org:10.1002/pbc.24271>
- 40 Weigel, B. *et al.* Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. *Pediatr Blood Cancer* **61**, 452-456 (2014). <https://doi.org:10.1002/pbc.24605>
- 41 Kolb, E. A. *et al.* A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report. *Pediatr Blood Cancer* **62**, 751-758 (2015). <https://doi.org:10.1002/pbc.25464>
- 42 Loh, M. L. *et al.* A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). *Pediatr Blood Cancer* **62**, 1717-1724 (2015).  
<https://doi.org:10.1002/pbc.25575>
- 43 Geller, J. I. *et al.* A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). *Pediatr Blood Cancer* **64** (2017).  
<https://doi.org:10.1002/pbc.26565>
- 44 Chuk, M. K. *et al.* A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group. *Pediatr Blood Cancer* **65**, e27077 (2018). <https://doi.org:10.1002/pbc.27077>
- 45 Geller, J. I. *et al.* A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and



- pilot consortium trial (ADV1315). *Cancer* **124**, 4548-4555 (2018).  
<https://doi.org:10.1002/cncr.31725>
- 46 Norris, R. E. *et al.* Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADV1213). *Pediatr Blood Cancer* **65**, e26944 (2018). <https://doi.org:10.1002/pbc.26944>
- 47 Schafer, E. S. *et al.* A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADV1314). *Pediatr Blood Cancer* **65**, e27066 (2018).  
<https://doi.org:10.1002/pbc.27066>
- 48 Doz, F. *et al.* Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. *Pediatr Blood Cancer* **66**, e27900 (2019).  
<https://doi.org:10.1002/pbc.27900>
- 49 Jannier, S. *et al.* SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers. *Cancers (Basel)* **12** (2020).  
<https://doi.org:10.3390/cancers12103051>
- 50 Schafer, E. S. *et al.* Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADV1411). *Pediatr Blood Cancer* **67**, e28073 (2020).  
<https://doi.org:10.1002/pbc.28073>
- 51 Zhang, Y. T. *et al.* Novel treatment of refractory / recurrent pulmonary hepatoblastoma. *Pediatr Int* **62**, 324-329 (2020). <https://doi.org:10.1111/ped.14134>